AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35977769
Drug: Diazoxide 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazoxide 5 mg/kg orally loading dose, then 1.5 mg/kg every 12 hours maintenance dose, titrated to target BGC 2.6‐5.4 mmol/L
Trial: 34342893
Drug: Gel nail
RxNorm normalized name: urea Topical Gel [Kera Nail]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel nail polish application
Trial: 33932093
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of apremilast at 20, 30, or 40 mg
Trial: 33932093
Drug: Multiple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of apremilast at 30 mg b.i.d. for 14 days
Trial: 32548811
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of ascites, ALBI grade 2–3, serum ɑ-fetoprotein level ≥ 400 ng/mL, total tumor volume ≥ 396 cm3, presence of vascular invasion, poor performance status
Trial: 34263472
Drug: Edasalonexent softgel
RxNorm normalized name: Edasalonexent
DrugBank: Edasalonexent (DB15010)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edasalonexent softgel capsules (100 mg or 250 mg)
Trial: 36103415
Drug: Aggressive fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive fluid resuscitation (20 ml/kg bolus, followed by 3 ml/kg/hour)
Trial: 36103415
Drug: Moderate fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate fluid resuscitation (10 ml/kg bolus for hypovolemia or no bolus for normovolemia, followed by 1.5 ml/kg/hour)
Trial: 35751772
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose tranexamic acid (TXA): 50 mg/kg, 5 mg/kg/hr
Trial: 36126603
Drug: Personalized swallowing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized swallowing rehabilitation twice a day for 10 days
Trial: 36078233
Drug: β‐endorphin levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐endorphin levels before chemotherapy
Trial: 36078233
Drug: β‐endorphin levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐endorphin levels after chemotherapy
Trial: 36078233
Drug: Serotonin levels
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin levels before chemotherapy
Trial: 34645654
Drug: SPACE intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SPACE intervention (automated search, pharmacist outreach, patient invitation for medication review)
Trial: 32557260
Drug: Zinc acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc acetate hydrate (ZAH; zinc, 50 mg/day)
Trial: 32557260
Drug: Polaprezinc (PPZ;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polaprezinc (PPZ; zinc, 34 mg/day)
Trial: 32557260
Drug: Pre-dialysis SCre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-dialysis SCre level ≥ 10.0 mg/dL
Trial: 35637624
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg CBD
Trial: 32729120
Drug: 1,500 mg
RxNorm normalized name: garlic 1,500 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,500 mg CBD
Trial: 35697050
Drug: SARS-CoV-2 recombinant
RxNorm normalized name: SARS-CoV-2 recombinant spike protein antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 recombinant protein vaccine (high dose)
Trial: 34332895
Drug: Topical lotilaner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lotilaner ophthalmic solution, 0.25%
Trial: 34668065
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Otosporin®
Trial: 34420980
Drug: Eteplirsen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eteplirsen treatment
Trial: 32220414
Drug: Buprenorphine initiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine initiation (8 mg sublingual buprenorphine or 8-2 mg sublingual buprenorphine/naloxone)
Trial: 34578900
Drug: High Protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Protein (HP) toddler milk formula (30 g protein, 10 g fat)
Trial: 34578900
Drug: Low Protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Protein (LP) toddler milk formula (7 g protein, 20 g fat)
Trial: 33023997
Drug: Respiratory therapist‐driven
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respiratory therapist‐driven oxygen titration after an electronic alert
Trial: 33023997
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (titration based on physician order)
Trial: 33057314
Drug: IV1 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV1 (single intravenous dose of 15 mg TXA/kg prior to skin incision)
Trial: 33408009
Drug: IV2 (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV2 (two intravenous doses of 15 mg TXA/kg: one prior to skin incision and one 6 hours after)
Trial: 33408009
Drug: TOP (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOP (2 g TXA in 50 ml of saline irrigated topically at the end of surgery)
Trial: 36123259
Drug: 20 IU/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 IU/kg Omtv + vaccine
Trial: 36123259
Drug: 40 IU/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 IU/kg Omtv + vaccine
Trial: 36123259
Drug: 20 IU/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 IU/kg HRIG + vaccine
Trial: 35570983
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + vaccine
Trial: 35604745
Drug: Marriage checkup
RxNorm normalized name: Cardui Mariae Fructus
DrugBank: Milk thistle (DB14375)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marriage checkup (active treatment)
Trial: 33536102
Drug: L-carnitine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (50 mg/kg/day)
Trial: 32871923
Drug: Hudi enteric-coated
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hudi enteric-coated capsules (HEC)
Trial: 32871923
Drug: Enteric-coated mesalazine
RxNorm normalized name: mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated mesalazine tablets placebo
Trial: 33557762
Drug: Individualized protocol
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized protocol (IP) group - individualized rescue morphine dosing based on fentanyl test results (10 μg/kg if positive, 50 μg/kg if negative)
Trial: 33557762
Drug: Conservative protocol
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative protocol (CP) group - fixed rescue morphine dosing (25 μg/kg)
Trial: 33119047
Drug: ω-3 fatty
RxNorm normalized name: ω-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω-3 fatty acids, 1 g per day
Trial: 35131155
Drug: Self-Monitored Blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-Monitored Blood Glucose (BGM) (4 times daily)
Trial: 35258101
Drug: Vericiguat 2.5
RxNorm normalized name: vericiguat 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vericiguat 2.5 mg (up-titrated to 5 mg and 10 mg) + nitroglycerin 0.4 mg sublingual
Trial: 35258101
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + nitroglycerin 0.4 mg sublingual
Trial: 35780177
Drug: Cold plasma
RxNorm normalized name: TITANIUM DIOXIDE 1.26 g in 30 g TOPICAL CREAM [Cold Plasma Plus Neck and Chest SPF25]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold plasma treatment combined with pyroligneous acid
Trial: 35780177
Drug: Cold plasma
RxNorm normalized name: TITANIUM DIOXIDE 1.26 g in 30 g TOPICAL CREAM [Cold Plasma Plus Neck and Chest SPF25]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold plasma treatment
Trial: 35780177
Drug: Seed plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seed plasma treatment combined with biochar application
Trial: 35780177
Drug: Seed plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seed plasma treatment with biochar
Trial: 33516285
Drug: Lumacaftor 200
RxNorm normalized name: lumacaftor 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumacaftor 200 mg–ivacaftor 250 mg orally once every 12 h for up to 120 weeks
Trial: 33516285
Drug: Lumacaftor–ivacaftor therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumacaftor–ivacaftor therapy
Trial: 38741174
Drug: Multiple micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrient supplements (MMS)
Trial: 32859250
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with oral medication
Trial: 32859250
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine treatment plan
Trial: 34376972
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.0 mg/kg bolus, 1.0 mg/kg/h until end of surgery)
Trial: 36299194
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (experimental group)
Trial: 39606414
Drug: Neoadjuvant androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant androgen deprivation therapy (NADT)
Trial: 36005919
Drug: Dry Cupping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry Cupping Therapy (DCT)
Trial: 36005919
Drug: Creatine Supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine Supplementation + Dry Cupping Therapy (CS+DCT)
Trial: 34734875
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment group (from RCTs)
Trial: 35027421
Drug: Corticocortical paired
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticocortical paired associative stimulation (ccPAS) in conjunction with conventional rehabilitation treatment, 10 interventions, 5 times a week for 2 weeks.
Trial: 35027421
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation treatment with sham stimulation.
Trial: 35027421
Drug: Corticocortical paired
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticocortical paired associative stimulation (ccPAS) in conjunction with conventional rehabilitation treatment.
Trial: 33142485
Drug: 5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g/kg star anise
Trial: 33142485
Drug: 0.22 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.22 g/kg essential oil
Trial: 33142485
Drug: 5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g/kg leavings
Trial: 34060731
Drug: Pycnogenol® (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pycnogenol® (150 mg daily in 3 doses of 50 mg)
Trial: 33575976
Drug: Self-assessed activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-assessed activities of daily living
Trial: 33575976
Drug: Research assistant-assessed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Research assistant-assessed activities of daily living
Trial: 33575976
Drug: Self-assessed instrumental
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-assessed instrumental activities of daily living
Trial: 33575976
Drug: Research assistant-assessed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Research assistant-assessed instrumental activities of daily living
Trial: 34893371
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (TA) using an eutectic mixture of lidocaine and prilocaine (EMLA)
Trial: 32656729
Drug: Liraglutide (subcutaneous)
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide (subcutaneous) 0.6 mg/day to 3.0 mg
Trial: 32656729
Drug: Liraglutide (subcutaneous)
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide (subcutaneous)
Trial: 32575611
Drug: Flaxseed lignan
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed lignan extract (50 mg/day secoisolariciresinol diglucoside)
Trial: 32575611
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Flaxseed lignan and Placebo)
Trial: 35502668
Drug: Oliceridine injection
RxNorm normalized name: oliceridine Injection
DrugBank: Oliceridine (DB14881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oliceridine injection
Trial: 33831552
Drug: Exenatide twice
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide twice a day plus glargine
Trial: 33831552
Drug: Aspart 70/30
RxNorm normalized name: INSULIN,ASPART 70/30 NOVOLOG FLEXPEN 3ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspart 70/30 twice a day
Trial: 32242395
Drug: Western Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western Medicine (cetirizine hydrochloride, vitamin C, and vitamin B complex)
Trial: 34807286
Drug: Transurethral cystolitholapaxy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral cystolitholapaxy plus medical therapy (tamsulosin plus finasteride)
Trial: 32247061
Drug: Elective treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective treatment
Trial: 32763021
Drug: Active placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo (remifentanil infused to a target plasma concentration of 1.7 ng/mL)
Trial: 33600538
Drug: Conus interface
RxNorm normalized name: Blitum bonus-henricus pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conus interface implants
Trial: 33600538
Drug: Flat-to-flat interface
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flat-to-flat interface implants
Trial: 33600538
Drug: Platform-switched interface
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform-switched interface implants
Trial: 32515058
Drug: Befriending Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befriending Therapy (BT)
Trial: 35413932
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of umbilical cord-derived Wharton’s jelly mesenchymal stromal cells (WJ-MSCs)
Trial: 35413932
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of umbilical cord-derived Wharton’s jelly mesenchymal stromal cells (WJ-MSCs)
Trial: 35765084
Drug: Robot-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted therapy (30-min Armguider robot-assisted therapy, 5 days a week for 6 weeks)
Trial: 35765084
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (6 weeks)
Trial: 32278266
Drug: Off-label prescription
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Off-label prescription after 2018
Trial: 32278266
Drug: Under indication
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Under indication prescription
Trial: 32264949
Drug: Non‐patch group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐patch group
Trial: 34550862
Drug: Sound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sound therapy (ST) with virtual reality (VR) stimuli
Trial: 34550862
Drug: Sound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sound therapy (ST) alone
Trial: 35835265
Drug: Investigational regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational regimen to increase and maintain plasma potassium (p-K) at high-normal levels (4.5-5.0 mmol/l)
Trial: 33736617
Drug: Group meta-cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group meta-cognitive therapy
Trial: 35021194
Drug: Green-MED diet
RxNorm normalized name: acid green 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green-MED diet (Mankai 100 g/d, green tea 3-4 cups/d, +800 mg/d polyphenols)
Trial: 35021194
Drug: Mediterranean diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean diet (MED) (28 g walnuts/d, +440 mg/d polyphenols)
Trial: 33226139
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg every 2 weeks for 52 weeks (Arm A)
Trial: 33226139
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg every 2 weeks for 24 weeks, followed by every 4 weeks for 28 weeks (Arm B)
Trial: 36498758
Drug: Fu's subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fu's subcutaneous needling (FSN)
Trial: 32005340
Drug: 8-week internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week internet-based cognitive behavioral therapy (CBT)
Trial: 33957937
Drug: Robotic-therapy Group
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic-therapy Group (RG) - 20 sessions of 45 min each, five days a week for four weeks
Trial: 33957937
Drug: Robotic-therapy Group
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic-therapy Group (RG)
Trial: 33771278
Drug: 4 weeks
RxNorm normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of standardized outpatient treatment (cognitive behavioral therapy)
Trial: 33771278
Drug: 16 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16 weeks of standardized outpatient treatment (cognitive behavioral therapy)
Trial: 33771278
Drug: Completion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completion of treatment (regardless of group assignment)
Trial: 36184583
Drug: Modified application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified application of COOK Cervical Ripening Balloon (CCRB) with uterine balloon filled to 120 mL and vaginal balloon filled to 40 mL, with light traction applied and removed after 12 hours.
Trial: 32444264
Drug: Pharmacologic prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic prophylaxis (subcutaneous heparin) plus routine care
Trial: 35861861
Drug: CT-guided external
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-guided external beam radiation therapy (EBRT)
Trial: 33215284
Drug: No levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: No levodopa treatment strategies
Trial: 33215284
Drug: Levodopa with
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa with other medications
Trial: 35075087
Drug: Kinesio Taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesio Taping (KT) in combination with standard rehabilitation protocol
Trial: 34129953
Drug: Gamification intervention
RxNorm normalized name: Gamifant
DrugBank: Emapalumab (DB14724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gamification intervention with social incentives (participants receive a Fitbit Inspire 2 and select a daily step goal, enrolled in a game with loss-framed points and levels)
Trial: 34129953
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (participants receive a Fitbit Inspire 2 and select a daily step goal without gamification)
Trial: 34802002
Drug: UControlDrink smartphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UControlDrink smartphone app (UCD) with treatment as usual (TAU)
Trial: 34640468
Drug: Mindfulness-based stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based stress reduction (MBSR) group therapy
Trial: 35927828
Drug: Syrup placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syrup placebo
Trial: 32819681
Drug: Intravenous metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoprolol (up to 15 mg) before primary percutaneous coronary intervention
Trial: 32819681
Drug: Conventional STEMI
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional STEMI therapy
Trial: 32819681
Drug: Early intravenous
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intravenous metoprolol in patients with GLS ≥ -11.5%